Abstract
The SAR study of a series of 6-aryloxymethyl-8-aryl substituted quinolines is described. Optimization of the series led to the discovery of compound 26b, a highly potent (IC50=0.6 nM) and selective PDE4D inhibitor with a 75-fold selectivity over the A, B, and C subtypes and over 18,000-fold selectivity against other PDE family members. Rat pharmacokinetics and tissue distribution are also summarized.
Copyright (c) 2010 Elsevier Ltd. All rights reserved.
MeSH terms
-
Animals
-
Asthma / drug therapy
-
Cyclic Nucleotide Phosphodiesterases, Type 4 / metabolism*
-
Humans
-
Inhibitory Concentration 50
-
Male
-
Phosphodiesterase Inhibitors / chemical synthesis
-
Phosphodiesterase Inhibitors / chemistry*
-
Phosphodiesterase Inhibitors / pharmacokinetics
-
Phosphodiesterase Inhibitors / pharmacology*
-
Quinolines / chemical synthesis
-
Quinolines / chemistry*
-
Quinolines / pharmacokinetics
-
Quinolines / pharmacology*
-
Rats
-
Rats, Wistar
-
Structure-Activity Relationship
Substances
-
Phosphodiesterase Inhibitors
-
Quinolines
-
Cyclic Nucleotide Phosphodiesterases, Type 4